A phase I study of BAY 43–9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC)
Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 3067-3067
10.1200/jco.2005.23.16_suppl.3067